0001169245-21-000106.txt : 20211108
0001169245-21-000106.hdr.sgml : 20211108
20211108182609
ACCESSION NUMBER: 0001169245-21-000106
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20211105
FILED AS OF DATE: 20211108
DATE AS OF CHANGE: 20211108
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Hutson Nancy J
CENTRAL INDEX KEY: 0001379222
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38697
FILM NUMBER: 211389272
MAIL ADDRESS:
STREET 1: 64 MONTAUK AVENUE
CITY: STONINGTON
STATE: CT
ZIP: 06378
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: PhaseBio Pharmaceuticals Inc
CENTRAL INDEX KEY: 0001169245
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 030375697
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 1 GREAT VALLEY PARKWAY
STREET 2: SUITE 30
CITY: MALVERN
STATE: PA
ZIP: 19355
BUSINESS PHONE: (610) 981-6500
MAIL ADDRESS:
STREET 1: 1 GREAT VALLEY PARKWAY
STREET 2: SUITE 30
CITY: MALVERN
STATE: PA
ZIP: 19355
FORMER COMPANY:
FORMER CONFORMED NAME: Phase Biosciences Inc
DATE OF NAME CHANGE: 20061013
FORMER COMPANY:
FORMER CONFORMED NAME: DT BIOSCIENCES INC
DATE OF NAME CHANGE: 20020315
4
1
wf-form4_163641394792074.xml
FORM 4
X0306
4
2021-11-05
0
0001169245
PhaseBio Pharmaceuticals Inc
PHAS
0001379222
Hutson Nancy J
C/O PHASEBIO PHARMACEUTICALS, INC.
1 GREAT VALLEY PARKWAY, SUITE 30
MALVERN
PA
19355
1
0
0
0
Common Stock
2021-11-05
4
M
0
24860
2.26
A
24860
D
Common Stock
2021-11-05
4
M
0
1500
3.15
A
26360
D
Common Stock
2021-11-08
4
M
0
7400
3.15
A
33760
D
Non-employee Director Stock Option (right to buy)
2.26
2021-11-05
4
M
0
24860
2.26
D
2028-05-03
Common Stock
24860.0
2256
D
Non-employee Director Stock Option (right to buy)
3.15
2021-11-05
4
M
0
1500
3.15
D
2029-02-27
Common Stock
1500.0
7400
D
Non-employee Director Stock Option (right to buy)
3.15
2021-11-08
4
M
0
7400
3.15
D
2029-02-27
Common Stock
7400.0
0
D
The stock option shall vest with respect to 25% of the shares on February 21, 2019, and shall vest in 36 additional monthly installments thereafter, subject to the reporting person's continued service through each such date.
The shares subject to the option shall vest in equal monthly installments over 36 months from October 17, 2018, subject to the reporting person's continued service through each such date.
/s/ John P. Sharp, Attorney-in-fact
2021-11-08